Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

BACKGROUND: DNA mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is not responsive to pembrolizumab monotherapy. DNA methyltransferase inhibitors can promote antitumor immune responses. This clinical trial investigated whether concurrent treatment with azacitidine enhances the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuang, Chaoyuan, Park, Yongseok, Augustin, Ryan C., Lin, Yan, Hartman, Douglas J., Seigh, Lindsey, Pai, Reetesh K., Sun, Weijing, Bahary, Nathan, Ohr, James, Rhee, John C., Marks, Stanley M., Beasley, H. Scott, Shuai, Yongli, Herman, James G., Zarour, Hassane M., Chu, Edward, Lee, James J., Krishnamurthy, Anuradha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740438/
https://www.ncbi.nlm.nih.gov/pubmed/34991708
http://dx.doi.org/10.1186/s13148-021-01226-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740438/
https://www.ncbi.nlm.nih.gov/pubmed/34991708
http://dx.doi.org/10.1186/s13148-021-01226-y

Ejemplares similares